Today's guest post comes from Meghal Patel, Chief Product Officer for Truzo at Model N. Meghal examines why claims-level transparency has become increasingly important as manufacturers navigate the growing complexity of 340B and other drug pricing programs. He argues that greater visibility into pricing, discounts, and utilization can help manufacturers move beyond compliance to improve gross-to-net (GTN) management, revenue forecasting, and strategic decision-making. To learn more, watch the webinar: From Program Silos to GTN Transparency: A Unified View with Model N + Truzo . Read on for Meghal's insights. Read more » © 2006-2026 HMP Omnimedia, LLC d/b/a Drug Channels…
Today's guest post comes from Meghal Patel, Chief Product Officer for Truzo at Model N.
Meghal examines why claims-level transparency has become increasingly important as manufacturers navigate the growing complexity of 340B and other drug pricing programs. He argues that greater visibility into pricing, discounts, and utilization can help manufacturers move beyond compliance to improve gross-to-net (GTN) management, revenue forecasting, and strategic decision-making.
To learn more, watch the webinar:
From Program Silos to GTN Transparency: A Unified View with Model N + Truzo.
Read on for Meghal's insights.
Read more »
US Pharma Marketing
